乳腺癌区域淋巴结放疗中度大分割早期毒性:HypoG-01 III期试验首次结果
HypoG-01是一项随机对照多中心非劣效III期试验,比较术后区域淋巴结中度大分割放疗(40 Gy/15次,3周)与常规分割放疗(50 Gy/25次,5周)的毒性和疗效。1260例T1-3 N0-3 M0乳腺癌患者纳入意向治疗分析,3周组最大≥2级不良事件比例为45%,5周组为51.8%。早期不良事件总体轻微,3周方案在区域淋巴结放疗女性中未引起安全性担忧。
要点
- 3周组最大≥2级不良事件284例(45%),5周组326例(51.8%)。
- 总体3级不良事件88例(7%),4级1例,无5级不良事件。
- 保乳术后6个月美容评估优良率88.4%,两组间无失衡。
核心结论
- 早期不良事件总体轻微,3周中度大分割放疗在区域淋巴结放疗女性中未引起安全性担忧。
研究设计与样本
- 随机、对照、多中心、非劣效III期试验,2016年9月至2020年3月共29个中心入组1265例女性。
- 入组标准为≥18岁、T1-3 N0-3 M0乳腺癌,术后±系统治疗后1:1随机接受40 Gy/15次(3周)或50 Gy/25次(5周)±瘤床推量。
- 在意向治疗人群(1260例,3周组631例、5周组629例)中分析基线、治疗结束和6个月随访的不良事件。
主要发现
- 3周组最大≥2级不良事件284例(45%),5周组326例(51.8%)。
- 总体3级不良事件88例(7%),4级1例,无5级不良事件。
- 报告的不良事件主要为皮炎、乏力和疼痛,3周组数值上低于5周组。
- 接受瘤床推量或BMI>30的患者≥2级皮炎更常见,但即使在上述亚组中3周组仍数值上低于5周组。
- 保乳术后6个月完成美容评估的552例患者中,88.4%美容结果优良至良好,两组间无失衡。
关键数值与推荐
- 不良事件采用CTCAE v4.0、LENT/SOMA和Harris 4点量表分级。
- 主要比较方案为40 Gy/15次(3周)与50 Gy/25次(5周)±瘤床推量。
临床怎么用
- 对于接受区域淋巴结放疗的乳腺癌患者,3周中度大分割方案早期不良事件轻微,未引起安全性担忧。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate early adverse events (AEs) in HypoG-01, a randomised, controlled, multicentre, non-inferiority phase 3 trial comparing toxicity and efficacy of adjuvant loco-regional moderately hypofractionated radiation therapy versus 2 Gy daily radiation therapy. METHODS: Women ≥ 18 years with T1-3 N0-3 M0 breast cancer were randomised 1:1 after surgery +/- systemic therapy to receive either 40 Gy/15 fractions (3-week-RT) or 50 Gy/25 fractions (5-week-RT) +/-tumour-bed boost. AEs at baseline, end of treatment, and 6-month follow-up were graded using CTCAEV4.0, LENT/SOMA and Harris 4-point scales. Competing risk analysis for cumulative incidence of AEs, worst grade dermatitis according to risk factors, and cosmetic assessment were performed in the intention-to-treat (ITT) population. RESULTS: From September 2016 to March 2020, 29 sites enrolled 1265 women. The ITT population included 1260 patients (3-week-RT: 631, 5-week-RT: 629). The proportion of patients with maximum grade ≥ 2 AEs were 284 (45 %) in 3-week-RT and 326 (51.8 %) in 5-week-RT. Overall, 88 (7 %) grade 3, one grade 4 and no grade 5 AEs were observed. Reported AEs were mostly dermatitis, fatigue, and pain, numerically lower in 3-week-RT than 5-week-RT. Grade ≥ 2 dermatitis was more frequent in patients receiving a tumour-bed boost or with BMI > 30 but numerically less frequent with 3-week-RT than 5-week-RT even in those subgroups. Of the 552 patients with breast-conserving surgery who completed cosmetic evaluation at M6, 88.4 % had excellent to good cosmetic results with no imbalance between groups. CONCLUSION: Early AEs were mild and do not raise safety concerns for 3-week-RT in women receiving nodal RT.
引用
- Brion T, Ghodssighassemabadi R, Auzac G, et al. Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial. Radiother Oncol. 2025. PMID: 40097073. doi:10.1016/j.radonc.2025.110849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。